(Morgan Hill, CA; June 23, 2011)—Aragen Bioscience, Inc., a preclinical contract research and development organization located in the San Francisco Bay Area, recently announced the offering of in vivo services in compliance with GLP regulations. Previously, the company provided only non-GLP services focused on early stage research and discovery.
“With the implementation of GLP services in our rodent facility, we can now offer our clients a seamless transition from early stage research studies into the GLP compliant studies necessary to support IND submissions to the FDA,” commented Aragen’s President and CEO, Rick Srigley.
Aragen’s in vitro services continue be performed under non-GLP conditions, but Aragen intends to expand its services to include GLP compliant cell-based assays in the near future.
About Aragen Bioscience
Aragen Bioscience, Inc., is a research and development services company located in the San Francisco Bay area. Aragen Bioscience specializes in recombinant cell line and hybridoma development, cell culture and protein purification process development and production, primary and immortalized cell-based assays, in vivo models of human disease and custom immunological services. For more information, visit www.aragenbio.com.